Revised Again: Alzheimer's Diagnostic Criteria Get Another Makeover
The newly proposed scheme uses only amyloid and tau for diagnosis and staging. It establishes parallel tracks for fluid or imaging markers, and recognizes a clinical stage zero.
587 RESULTS
Sort By:
The newly proposed scheme uses only amyloid and tau for diagnosis and staging. It establishes parallel tracks for fluid or imaging markers, and recognizes a clinical stage zero.
The ability to quickly detect cerebral amyloid angiopathy and ARIA would make amyloid immunotherapy safer, but research in this area is just beginning.
First data from the Longitudinal Early-Onset Alzheimer’s Disease Study hints at what might cause this type of AD and how it unfolds.
Scientists have established acute slice recordings from cerebral cortex biopsies. They find circuitry and basic function to be preserved. They also find changes in the presence of Alzheimer's pathology.
Every week in a Finnish operating room, bits of human cortex get lifted from brains and straight into electrophysiology rigs. Other tissues go to diagnostic and research labs, or biobanks, for ADRD research. Read how it happens.
In the Finnish city of Kuopio, surgeons and scientists have built a unique protocol. It improves life for people with hydrocephalus—and it banks cortical tissue rife with preclinical pathology and gene variants for Alzheimer's research.
The Elecsys-based assay could run on 100,000 fully automated diagnostic machines worldwide.
Feeding taurine to mice and monkeys increased the lifespan of the former and reduced signs of aging in both.
In cognitively unimpaired older adults, some gut bacteria correlated with plaques and tangles, but not neurodegeneration.
Among cognitively healthy people, amyloid load tracked with blood p-tau181 and tangles only in those with high blood GFAP.
Three reviews, two perspectives, and four comments discuss recent advances and opportunities for dementia research.
While memory problems plague some people with lingering COVID symptoms, researchers do not yet understand what is going wrong in their brains.
Safety and cerebrospinal fluid tau data from the six-month Phase 1 trial are now published.
Clearance triggers improvement in downstream markers of inflammation and neurodegeneration—but not in those who started with high tangle burden. (Clue: women.)
NPTX2 binds complement C1q, disrupting signals to microglia to destroy synapses.